Vikas Bansal1, Kiran S Mahapure2, Abhishek Bhurwal3, Ishita Gupta4, Sahar Hassanain5, Janaki Makadia6, Nimisha Madas7, Paige Armaly8, Romil Singh9, Ishita Mehra10,11, John C O'Horo12, Rahul Kashyap1. 1. Department of Anaesthesiology and Critical Care Medicine, Mayo Clinic, Rochester, MN, United States. 2. Senior Resident, Department of Plastic Surgery, KAHER J. N. Medical College, Belgaum, India. 3. Department of Gastroenterology and Hepatology, Rutgers Robert Wood Johnson School of Medicine, New Brunswick, NJ, United States. 4. Dr. Rajendra Prasad Government Medical College, Tanda, India. 5. Women Medical College, Abbottabad, Pakistan. 6. Gujrat Medical Education and Research Society Medical College, Vadodara, India. 7. Mamata Medical College, Khammam, India. 8. University of the West Indies, Nassau, Bahamas. 9. Departments of Medicine, Metropolitan Hospital, Jaipur, India. 10. Division of Pulmonary, Sleep and Critical Care Medicine, Mayo Clinic, Rochester, MN, United States. 11. Department of Internal Medicine, North Alabama Medical Center, Florence, AL, United States. 12. Department of Infectious Disease, Department of Anesthesiology and Critical Care Medicine, Mayo Clinic, Rochester, MN, United States.
Abstract
Importance/Background: During current public health emergency of COVID-19 pandemic, repurposing of existing antiviral drugs may be an efficient strategy since there is no proven effective treatment. Published literature shows Remdesivir has broad-spectrum antiviral activity against numerous RNA viruses and has been recently recognized as a promising therapy against SARS-CoV-2. Methods: A systematic search was conducted for full length manuscripts published between inception and July 19th, 2020 focussing on efficacy and safety of Remdesivir in COVID-19. The primary outcomes were defined as mortality rate and median days to recovery based on the available pooled data. The secondary outcome was adverse events rate and drug discontinuation rate. Statistical Analysis: All outcomes were performed using Comprehensive Meta-Analysis software package (Bio stat, Englewood, NJ, USA). Results: A total of 1,895 patients from 9 studies were included in this qualitative synthesis. In patients treated with Remdesivir, the mean recovery time was 15.84 days (95% CI 11.68-20, SE 2.12; I 2 = 97.24) and the pooled mortality rate was 11.3% (95% CI 7.9-16%; I 2 = 74.85). However, treatment with Remdesivir was associated with adverse effects (55.3%, 95% CI 31.5-76.9%; I 2 = 97.66) eventually warranting the discontinuation of the drug (17.8%, 95% CI 8.6-33.1%; I 2 = 95.64). The meta-analysis of three clinical trials indicated that administration of Remdesivir significantly reduces the mortality compared to the placebo (OR 0.70, 95% CI 0.58-0.84, p ≤ 0.001; I 2 = 16.6). Conclusions and Relevance: The result of contemporary meta-analysis suggests mortality benefit with Remdesivir in COVID-19 and median recovery time was over 2 weeks. The pooled mortality with Remdesivir was found to be very low, and this analysis can shed light on this potential treatment for COVID-19 patients.
Importance/Background: During current public health emergency of COVID-19 pandemic, repurposing of existing antiviral drugs may be an efficient strategy since there is no proven effective treatment. Published literature shows Remdesivir has broad-spectrum antiviral activity against numerous RNA viruses and has been recently recognized as a promising therapy against SARS-CoV-2. Methods: A systematic search was conducted for full length manuscripts published between inception and July 19th, 2020 focussing on efficacy and safety of Remdesivir in COVID-19. The primary outcomes were defined as mortality rate and median days to recovery based on the available pooled data. The secondary outcome was adverse events rate and drug discontinuation rate. Statistical Analysis: All outcomes were performed using Comprehensive Meta-Analysis software package (Bio stat, Englewood, NJ, USA). Results: A total of 1,895 patients from 9 studies were included in this qualitative synthesis. In patients treated with Remdesivir, the mean recovery time was 15.84 days (95% CI 11.68-20, SE 2.12; I 2 = 97.24) and the pooled mortality rate was 11.3% (95% CI 7.9-16%; I 2 = 74.85). However, treatment with Remdesivir was associated with adverse effects (55.3%, 95% CI 31.5-76.9%; I 2 = 97.66) eventually warranting the discontinuation of the drug (17.8%, 95% CI 8.6-33.1%; I 2 = 95.64). The meta-analysis of three clinical trials indicated that administration of Remdesivir significantly reduces the mortality compared to the placebo (OR 0.70, 95% CI 0.58-0.84, p ≤ 0.001; I 2 = 16.6). Conclusions and Relevance: The result of contemporary meta-analysis suggests mortality benefit with Remdesivir in COVID-19 and median recovery time was over 2 weeks. The pooled mortality with Remdesivir was found to be very low, and this analysis can shed light on this potential treatment for COVID-19patients.
Authors: Ethan M Balk; Peter A L Bonis; Harry Moskowitz; Christopher H Schmid; John P A Ioannidis; Chenchen Wang; Joseph Lau Journal: JAMA Date: 2002-06-12 Impact factor: 56.272
Authors: Timothy P Sheahan; Amy C Sims; Rachel L Graham; Vineet D Menachery; Lisa E Gralinski; James B Case; Sarah R Leist; Krzysztof Pyrc; Joy Y Feng; Iva Trantcheva; Roy Bannister; Yeojin Park; Darius Babusis; Michael O Clarke; Richard L Mackman; Jamie E Spahn; Christopher A Palmiotti; Dustin Siegel; Adrian S Ray; Tomas Cihlar; Robert Jordan; Mark R Denison; Ralph S Baric Journal: Sci Transl Med Date: 2017-06-28 Impact factor: 17.956
Authors: Ariane J Brown; John J Won; Rachel L Graham; Kenneth H Dinnon; Amy C Sims; Joy Y Feng; Tomas Cihlar; Mark R Denison; Ralph S Baric; Timothy P Sheahan Journal: Antiviral Res Date: 2019-06-21 Impact factor: 5.970
Authors: Michelle L Holshue; Chas DeBolt; Scott Lindquist; Kathy H Lofy; John Wiesman; Hollianne Bruce; Christopher Spitters; Keith Ericson; Sara Wilkerson; Ahmet Tural; George Diaz; Amanda Cohn; LeAnne Fox; Anita Patel; Susan I Gerber; Lindsay Kim; Suxiang Tong; Xiaoyan Lu; Steve Lindstrom; Mark A Pallansch; William C Weldon; Holly M Biggs; Timothy M Uyeki; Satish K Pillai Journal: N Engl J Med Date: 2020-01-31 Impact factor: 91.245
Authors: B G Murphy; M Perron; E Murakami; K Bauer; Y Park; C Eckstrand; M Liepnieks; N C Pedersen Journal: Vet Microbiol Date: 2018-04-22 Impact factor: 3.293
Authors: Ahmed S Ali; Ibrahim M Ibrahim; Abdulhadi S Burzangi; Ragia H Ghoneim; Hanin S Aljohani; Hamoud A Alsamhan; Jehan Barakat Journal: Arab J Chem Date: 2021-08-16 Impact factor: 5.165
Authors: Aysun Tekin; Shahraz Qamar; Romil Singh; Vikas Bansal; Mayank Sharma; Allison M LeMahieu; Andrew C Hanson; Phillip J Schulte; Marija Bogojevic; Neha Deo; Simon Zec; Diana J Valencia Morales; Katherine A Belden; Smith F Heavner; Margit Kaufman; Sreekanth Cheruku; Valerie C Danesh; Valerie M Banner-Goodspeed; Catherine A St Hill; Amy B Christie; Syed A Khan; Lynn Retford; Karen Boman; Vishakha K Kumar; John C O'Horo; Juan Pablo Domecq; Allan J Walkey; Ognjen Gajic; Rahul Kashyap; Salim Surani Journal: World J Crit Care Med Date: 2022-03-09
Authors: Sherief Abd-Elsalam; Marwa Salama; Shaimaa Soliman; Ahmed Mohamed Naguib; Ibrahim S Ibrahim; Mohamed Torky; Mohamed Samir Abd El Ghafar; Enas Abdul-Raouf M Abdul-Baki; Mohammed Elhendawy Journal: Am J Trop Med Hyg Date: 2021-09-10 Impact factor: 3.707
Authors: Abhishek Bhurwal; Carlos D Minacapelli; Evan Orosz; Kapil Gupta; Christopher Tait; Ishita Dalal; Clark Zhang; Eric Zhao; Vinod K Rustgi Journal: World J Gastroenterol Date: 2021-12-14 Impact factor: 5.742